Inclusion Criteria:

          -  Diagnosis of the following tumor types

               -  Non Hodgkin-lymphoma, including:

                    -  Diffuse large B-cell lymphoma: Histopathologic confirmation

                    -  Mantle cell lymphoma: Histopathologic confirmation

                    -  Follicular lymphoma, all grades: Histopathologic confirmation

                    -  Marginal zone lymphoma: Histopathologic confirmation

               -  Chronic lymphocytic leukemia: Histopathologic or flow cytometric confirmation

               -  Multiple myeloma: Histopathologic or flow confirmation

          -  Relapsed, refractory, or detectable disease after treatment with chimeric antigen
             receptor T-cells

             * Multiple Myeloma: patients must have exhausted all treatment options known to
             provide clinical benefit, and are refractory to a minimum of 3 prior lines of therapy
             (including an immunomodulatory imide drug [IMiD], proteasome inhibitor [PI], or
             anti-CD38 monoclonal antibody)

          -  Have measurable disease, defined by histology:

               -  Non-Hodgkin's lymphoma, based on presence of lesions >= 1.5 cm that can be
                  accurately measured in 2 dimensions by computed tomography (CT) (preferred) or
                  magnetic resonance imaging (MRI), and are not included in any prior field of
                  radiation therapy

               -  Chronic lymphocytic leukemia: circulating lymphocytes >= 5,000 / mm^3

               -  Multiple myeloma, based on the International Myeloma Working Group (IMWG)
                  criteria of having one or more of the following findings:

                    -  Serum M protein >= 1.0 g/dL

                    -  Urine M protein >= 200 mg/24 hours

                    -  Involved serum free light chain level >= 10 mg/dL with abnormal kappa/lambda
                       ratio

                    -  Measurable biopsy-proven plasmacytomas (>= 1 lesion has a single diameter >=
                       2 cm)

                    -  Bone marrow plasma cells >= 30%

          -  Have the capacity to give informed consent

          -  Anticipated survival of > 3 months

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0-2

          -  Estimated glomerular filtration rate (eGFR) >= 20 ml/min

          -  Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x upper limit
             of normal (ULN)

          -  Total bilirubin =< 2 x ULN

          -  Absolute neutrophil count (ANC) >= 1,000/uL

          -  Platelets >= 50,000/uL

          -  Hemoglobin >= 8 g/dL

        Exclusion Criteria:

          -  Receipt of intervening therapy after CAR T-cell infusion

          -  History of another primary malignancy that has not been in remission for at least 1
             year (with the exception of non-melanoma skin cancer, curatively treated localized
             prostate cancer, curatively treated superficial bladder cancer and cervical carcinoma
             in site on biopsy or a squamous intraepithelial lesion on papanicolaou [PAP] smear)

          -  Active hepatitis B, hepatitis C at time of screening

          -  Known (human immunodeficiency virus [HIV]) seropositivity

          -  Subjects with uncontrolled infection

          -  Concurrent use of other anticancer agents or experimental treatments

          -  Active autoimmune disease requiring immunosuppressive therapy with the exception of
             vitiligo and autoimmune alopecia

          -  Known active central nervous system (CNS) involvement

          -  Subjects with a condition requiring systemic treatment with either corticosteroids (>
             10 mg daily prednisone equivalent) or other immunosuppressive medications within 14
             days of study drug administration. Inhaled or topical steroids, and adrenal
             replacement doses are permitted in absence of active autoimmune disease

          -  Known history of any active infectious pneumonitis

          -  Receipt of prior anti PD-1 or PD-L1 therapy

          -  Presence of acute or chronic graft-versus-host disease (GVHD) requiring active
             treatment unless limited to skin involvement and managed with topical steroid therapy
             alone

          -  Has active cytokine release syndrome

          -  Pregnancy or breastfeeding: Women of childbearing potential (WOCBP) must have a
             negative serum or urine pregnancy test (urine pregnancy test: minimum sensitivity 25
             IU/L or equivalent units of human chorionic gonadotropin [hCG]) within 14 days of the
             first dose of study drug. Women must not be breastfeeding. Females of non-childbearing
             potential are those who are postmenopausal greater than 1 year or who have had a
             bilateral tubal ligation or hysterectomy. Females of childbearing potential and males
             who have partners of childbearing potential must agree to use 2 effective
             contraceptive methods during the study and for 8 months following the last dose of
             nivolumab